Financial Data and Key Metrics Changes - Omada Health achieved 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][30] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - GAAP net income was $5 million in Q4, marking the first quarter of profitability, and a full-year GAAP net loss of $13 million, an improvement from a loss of $47 million in 2024 [30][35] - Adjusted EBITDA for the full year was $6 million, with a margin of 2%, compared to a loss of $29 million in 2024 [35][36] Business Line Data and Key Metrics Changes - The GLP-1 Care Track program saw significant adoption, with over 150,000 members supported on GLP-1s, contributing to the overall growth in the cardiometabolic suite [10][19] - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][68] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million eligible lives [18] - The total addressable market for Omada is estimated at over $138 billion, with current penetration below 10% [19] Company Strategy and Development Direction - Omada's strategy focuses on innovation, effective programs, and a multi-condition platform to address cardiometabolic health [20][25] - The company plans to expand capabilities in GLP-1 prescribing, cholesterol management, and flexible care options to enhance its service offerings [12][24] - Investments in AI are aimed at improving member support and operational efficiency, with a focus on leveraging unique data sets for personalized care [14][65] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a clear plan for growth, emphasizing the importance of addressing chronic care solutions [4][10] - The healthcare system's inability to scale effectively without a different care model was highlighted, with Omada positioned to fill this gap [8][9] - The company anticipates continued strong growth driven by the demand for multi-condition care and effective enrollment strategies [30][38] Other Important Information - Omada's gross margins expanded significantly, with Q4 GAAP gross margin reaching 71%, up from 67% in the prior year [31] - The company generated positive operating cash flow for the full year and ended 2025 with $222 million in cash and cash equivalents [37] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions without assuming significant improvements in enrollment or engagement metrics [42][44] Question: What are the mechanics of the new GLP-1 Flex Care program? - The GLP-1 Flex Care program is designed to support employers who do not currently cover GLP-1s, providing a structured model for clinical evaluation and prescribing while allowing employees to purchase medications out-of-pocket [54][56] Question: How is Omada leveraging AI in its operations? - Omada is utilizing AI for coding assistance, member support, and enhancing the overall member experience, which is expected to improve margins [64][65] Question: What traction is being seen in the hypertension and diabetes programs? - Growth in diabetes and hypertension programs is strong, with both seeing year-over-year growth rates of 45% or more, reflecting the integrated approach to cardiometabolic care [66][68]

Core Insights - Omada Health, Inc. reported a significant revenue increase of 58% in the fourth quarter and 53% for the full year 2025, reaching $76 million and $260 million respectively [1][7] - The company achieved positive net income of $5 million in the fourth quarter, a notable improvement from a net loss of $8 million in the same quarter of 2024, and narrowed its full-year net loss to $13 million from $47 million in 2024 [8][7] - Omada delivered positive adjusted EBITDA of $8 million in the fourth quarter and $6 million for the full year, compared to adjusted EBITDA losses in the previous year [14][8] Member Growth - Total membership reached 886,000 by year-end 2025, reflecting a 55% year-over-year growth [3] Revenue and Financial Performance - Revenue for the fourth quarter was $76 million, up 58% year-over-year, while the full-year revenue was $260 million, up 53% compared to 2024 [7] - Gross margin improved to 71% in the fourth quarter from 67% in Q4 2024, and for the full year, it was 66%, up from 61% in 2024 [8] - Non-GAAP gross margin for the fourth quarter was 73%, up from 69% in Q4 2024, and for the full year, it was 68%, compared to 63% in 2024 [8] Program Innovations and Offerings - The company introduced GLP-1 Flex Care, a new option for employers to connect eligible employees with clinical evaluation and ongoing medical oversight for GLP-1s, enhancing access and affordability [7][5] - Omada launched AI-powered tools, OmadaSpark and Meal Map, to support members with wellness education alongside human coaches [7][5] - In February 2026, Omada announced a new program, Omada for Cholesterol, to address prevalent conditions often co-existing with diabetes and obesity, expanding its cardiometabolic care capabilities [7][5] Financial Outlook - For the year ending December 31, 2026, Omada expects revenue in the range of $312 million to $322 million, representing a midpoint growth of 22% compared to 2025 [15] - Adjusted EBITDA is projected to be between $7 million and $15 million [15]

Building a Between-Visit Provider As of March 5, 2026 Christine Real Omada Member Important Notice and Disclaimers Disclaimers Our Mission Bend the curve 3 3 This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "tar ...

Core Insights - Omada Health reported a revenue of $68 million for Q3 2025, representing a 49% increase year-over-year, with total members reaching 831,000, a 53% growth compared to Q3 2024 [1][7][8] - The company achieved a significant reduction in net loss, reporting a net loss of $3 million compared to $9 million in Q3 2024, and recorded its first quarter of positive adjusted EBITDA at $2 million [1][8] - Omada announced a new GLP-1 prescribing offering aimed at enhancing member health outcomes and providing cost savings for customers [1][7][8] Financial Performance - Revenue for Q3 2025 was $68 million, up 49% from $45.5 million in Q3 2024 [7][8] - Gross margin improved to 66%, up from 63% in the same quarter last year, with a non-GAAP gross margin of 68% [8] - Adjusted EBITDA was reported at $2 million, a significant improvement from an adjusted EBITDA loss of $5 million in Q3 2024 [8] Member Growth and Offerings - Total members increased to 831,000, marking a 53% growth compared to the previous year [7] - The new GLP-1 prescribing offering will integrate Omada's behavior change program with medication management for anti-obesity medications [7] - The company published its 30th peer-reviewed manuscript, demonstrating cost savings from its Joint & Muscle Health program and showing that members largely maintained their weight one year after discontinuing GLP-1 therapy [7] Cash Position and Financial Outlook - Cash and cash equivalents stood at $199 million as of September 30, 2025 [8] - For the full year 2025, Omada expects revenue in the range of $251.5 million to $254.5 million, an increase from the previous range of $235 million to $241 million [8]

Core Insights - Omada Health has appointed Dr. Thomas Tsang as Chief Medical Officer to lead its clinical organization and enhance clinical quality and innovation [1][2][4] Company Overview - Omada Health is a virtual-first healthcare provider focused on chronic conditions such as diabetes, hypertension, and musculoskeletal issues, serving over 2,000 customers including health plans and Fortune 500 companies [5][6] - The company has implemented clinically-validated behavior change protocols and has over a decade of experience with 30 peer-reviewed publications demonstrating its clinical and economic results [5] Leadership and Experience - Dr. Tsang has a strong background in virtual care delivery, having previously served as founding CEO of Valera Health, where he raised over $75 million and scaled the company to over 500 employees [2][3] - His experience includes roles as Chief Medical Officer at Merck Healthcare Services and as a Medical Director under the Obama Administration, contributing to national health policy and electronic health records [3] Strategic Initiatives - Omada is expanding its GLP-1 Care Track, which has served over 100,000 members since its launch, and enhancing its AI capabilities with tools like OmadaSpark and Meal Map for personalized nutrition [4] - The company aims to combine innovative technology with human-led care to improve member engagement and health outcomes [4]

Core Insights - Omada Health has launched Meal Map, a new AI-powered tool designed to enhance meal tracking and member engagement in its cardiometabolic programs, focusing on nutrient quality rather than restrictive dieting [1][2][3] Company Overview - Omada Health is a virtual-first healthcare provider that implements clinically-validated behavior change protocols for individuals with chronic conditions such as diabetes and hypertension, serving over 2,000 customers including health plans and employers [5][6] Product Features - Meal Map provides instant feedback on the nutrient composition of meals and weekly progress reports on nutritional quality and water intake, aiming to improve members' relationship with food by promoting a nutrient-dense approach [2][3][4] - The tool is integrated with OmadaSpark, an AI-powered nutrition education tool that offers dietitian-vetted recipes based on tracked meals [3] Market Positioning - The introduction of Meal Map addresses a gap in the market for tools that prioritize nutritional value over calorie counting, aligning with the growing demand for sustainable health approaches beyond fad diets [2][4]

Core Viewpoint - Omada Health, Inc. reported strong financial results for the second quarter of 2025, highlighting a 49% year-over-year revenue growth and significant member growth, indicating progress towards profitability [2][4]. Financial Performance - Revenue reached $61 million, representing a 49% increase compared to the second quarter of 2024 [8]. - Total members grew to 752,000, a 52% increase year-over-year [8]. - Gross margin improved to 66%, up from 60% in the same quarter of the previous year [9]. - Non-GAAP gross margin was 68%, compared to 63% in the second quarter of 2024 [9]. - The net loss narrowed to $5 million, down from a net loss of $11 million in the second quarter of 2024 [9]. - Adjusted EBITDA loss was $0.2 million, significantly improved from a loss of $6.8 million in the same quarter of 2024 [9]. Financial Outlook - For the year ending December 31, 2025, Omada expects revenue in the range of $235 million to $241 million [9]. - Adjusted EBITDA loss is projected to be between $9 million and $5 million [9]. Debt Management - On July 31, 2025, Omada fully repaid $31.0 million in principal and $0.4 million in accrued interest under its term loan facility and revolving line of credit, ahead of schedule [6]. Product and Service Development - The company has seen success with its GLP-1 companion programs, which are now available through two of the largest pharmacy benefit managers in the U.S. [8]. - In May, Omada introduced an AI-agent named OmadaSpark, aimed at providing real-time motivational interviewing and nutrition education to members [8]. Company Background - Omada Health is a virtual-first healthcare provider focused on chronic disease management, with over a decade of experience and a wide customer base exceeding 2,000 clients [11].

Core Viewpoint - The GLP-1 drug revolution continues to thrive in the first half of 2025, with Novo Nordisk's Wegovy and Eli Lilly's Zepbound emerging as star products, driving significant capital interest in the industry [2] Group 1: Omada Health - Omada Health, established in 2011, went public on June 6, 2025, at a price of $19 per share, raising approximately $150 million [3] - The stock surged to a high of $28 on its first day, closing at $23, marking a 21% increase and elevating the company's valuation to about $1.28 billion [3] - In 2024, Omada reported revenues of $169.8 million, a 38% year-over-year increase, with a gross margin of 60.6% [3] - By Q1 2025, revenues soared to $55 million, a 57% increase, while net losses decreased from $19 million to $9.4 million [3] - Omada's business model focuses on charging enterprises, health plans, and insurance channels for ongoing remote management services, filling the gap in health management between in-person visits [4] Group 2: Metsera - Metsera, founded in 2022, completed its IPO in January 2025 at $18 per share, raising $275 million [5] - The stock closed at $26.50 on its first day, reflecting a 47% increase, with an early high of over $35 [5] - Metsera's market capitalization was previously under $2 billion, but it is viewed as a strong contender in the anti-obesity sector [6] Group 3: Pipeline and Clinical Highlights - Metsera's lead product, MET-097i, is a long-acting GLP-1 receptor agonist showing promising results in early clinical trials, with an average weight loss of 11.3% over 12 weeks [7] - The drug demonstrates potential for monthly dosing, with a longer duration of action compared to competitors like Zepbound and Ozempic [7] - MET-233i, another product from Metsera, shows advantages in weight loss and pharmacokinetics, supporting monthly dosing [8] - Metsera's cash reserves post-IPO are approximately $590 million, ensuring operational sustainability until 2027 [9] Group 4: Industry Landscape - Other companies are also pursuing opportunities in the GLP-1 space, including Aardvark Therapeutics and BioAge Labs, which are building IPO frameworks and advancing their core pipelines [11][12] - The GLP-1 ecosystem is characterized by diverse technological pathways, providing investors with various options [14] Group 5: Investment Enthusiasm - The GLP-1 market is projected to exceed $100 billion by 2030, attracting significant investor interest [15] - Companies like Metsera and Omada are seen as having competitive advantages, such as long-acting formulations and extensive digital platforms [15] - Clinical milestones, such as Phase 3 trial initiations, are expected to act as catalysts for stock price increases [15]